IRINA ASHAMALLA: Open Payments
NPI 1205365772 · GLENDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$508 in 17 payments from 10 companies in 2025. Trend: 2023 $1,526 · 2024 $75 · 2025 $508
Food & beverage: $508
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 6 | $268 |
| Janssen Pharmaceuticals, Inc | 2 | $51 |
| ABBVIE INC. | 2 | $41 |
| Alkermes, Inc. | 1 | $29 |
| E.R. Squibb & Sons, L.L.C. | 1 | $25 |
| Bausch Health US, LLC | 1 | $25 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
Products named: FANAPT, SPRAVATO, VRAYLAR, ARISTADA, COBENFY, APLENZIN, Qelbree, Auvelity.
Industry payments across AZ — which companies pay providers there.
